Vivint Pharma投资400卢比,在海得拉巴建立一个肿瘤学和关键护理药物制造设施。 Vivint Pharma invests Rs 400 crore to set up a manufacturing facility in Hyderabad for oncology and critical care drugs.

注射制药公司Vivint Pharma正在投资400卢比,在海得拉巴的基因组谷地建立一个最先进的制造设施,重点是国内和国际市场的肿瘤学和关键护理药物。 Vivint Pharma, an injectable pharmaceutical company, is investing Rs 400 crore to set up a state-of-the-art manufacturing facility in Hyderabad's Genome Valley, focusing on oncology and critical care drugs for domestic and international markets. 预计该设施将雇用1 000人。 The facility is expected to employ 1,000 people. 这一投资与Vivint Pharma的战略是一致的,即利用印度的熟练劳动力和先进的制造能力来满足全球制药需求。 This investment aligns with Vivint Pharma's strategy to leverage India's skilled workforce and advanced manufacturing capabilities to meet global pharmaceutical demand.